Prognostic value of serum nicotinamide phosphoribosyltransferase in patients with bladder cancer

**Aim** To analyze the serum nicotinamide phosphoribosyltransferase (Nampt) level and its prognostic value in bladder cancer (BC).

**Methods** The study included 131 patients with transitional cell BC and 109 healthy controls from the West China Hospital of Sichuan University in the period between 2007 and 2013. Nampt concentration in serum was measured by commercial ELISA kits for human Nampt.

**Results** The serum Nampt protein level in patients with BC (mean ± standard deviation, 16.02 ± 7.95 ng/mL) was significantly higher than in the control group (6.46 ± 2.08 ng/mL) (P < 0.001). Serum Nampt level was an independent prognostic marker of non-muscle-invasive BC, with a higher serum Nampt level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio = 2.85, 95% confidence interval, 1.01-8.06; P = 0.048).

**Conclusion** Our results suggest that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC.

Received: December 31, 2013
Accepted: October 25, 2014

**Correspondence to:**
Lin Zhang
Department of Forensic Biology
West China School of Preclinical and Forensic Medicine, Sichuan University
Chengdu, People’s Republic of China
Chengdu 610041, PR China
zhanglin@scu.edu.cn
Bladder cancer (BC) is the ninth most common cancer diagnosis worldwide (1) and the most expensive cancer to treat (2). Among men it is the fourth most common cancer, with incidence four times higher than in women (3). In China, BC caused 17,365 deaths in 2005, with a steady increase in mortality between 1991 and 2005 (4). Of newly diagnosed BC cases, 70%-80% will present with non-muscle-invasive disease; 50%-70% will recur despite endoscopic and intravesical treatments, and 10%-30% will progress to muscle-invasive disease (5,6). Most recurrences occur within 5 years (7). Therefore, to develop improved, more effective prevention and treatments there is a need to find new biomarkers of tumorigenesis and prognosis of BC.

Nicotinamide phosphoribosyltransferase (Nampt) is a rate-limiting enzyme in the mammalian NAD⁺ biosynthesis of a salvage pathway (8). Previous studies have shown that it is significantly increased in primary colorectal cancer (9-11), lung cancer (12), breast cancer (13), prostate cancer (14) and gastric cancer (15). Thus, Nampt may be a good biomarker of malignant potential and stage progression (12,16). Our previous study revealed that genetic variants in \textit{NAMPT} may predict BC risk and prognosis (17). In the present study, we analyzed the serum Nampt level and its prognostic value in BC.

**MATERIALS AND METHODS**

**Study subjects**

The study enrolled 131 patients with transitional cell BC (mean ± standard deviation [SD], 63.49 ± 12.96 years) and 109 healthy controls (63.12 ± 10.28 years) (17). All participants were recruited between 2007 and 2013 from the West China Hospital of Sichuan University. The diagnosis of BC was confirmed by histological tissue examination from biopsy or resected specimens. Seventy-two patients had muscle-invasive and 59 had non-muscle-invasive BC (Table 1). The control group consisted of 109 healthy individuals who underwent a routine health survey in the same hospital. We excluded those patients who had previous cancer, received radiotherapy or chemotherapy, had metastasized cancer from other or unknown origin, or had any other serious disease. Control subjects were genetically unrelated to the patients and to each other. All participants were Han Chinese living in Sichuan province of the southwest China. The study was approved by the hospital ethics committee and all participants gave a written informed consent.

**Investigation of plasma protein expression levels of Nampt**

Serum was obtained after centrifuging blood samples at 1600 rpm for 10 min at 4°C and stored at -80°C until analysis. Nampt concentration in serum was measured by commercial ELISA kits for human Nampt (USCNK, Wuhan, China). The antibodies used in ELISA are specific for human Nampt. Analytical limit of detection of Nampt was 6.3 pg/mL. The results are expressed in ng/mL.

**rs61330082 genotyping**

\textit{rs61330082}, a single-nucleotide polymorphism (SNP) in the promoter region of \textit{NAMPT} gene, was genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method (17).

**Statistical analysis**

Data were analyzed using SPSS for Windows software package, version 16.0 (SPSS Inc., Chicago, IL, USA). The difference in Nampt expression levels between BC patients and control group was tested by \textit{t} test. The differences between serum Nampt level and genotypes of \textit{rs61330082} were tested by one-way ANOVA analysis. Odds ratio (OR)
and 95% confidence intervals (CI) were used to assess the effects of serum Nampt protein level on the clinicopathological factors.

Recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and the association of Nampt expression with RFS and OS was examined by a log-rank test. OS was the time from the day of diagnosis to the day of death or the last follow-up. RFS was the time from the day of diagnosis to the day of recurrence or death or the last follow-up. Prognostic factors were determined using Cox regression analysis. P value ≤0.05 was considered statistically significant.

**RESULTS**

**Nampt expression level**

The serum Nampt protein level in patients with BC (mean ± SD, 16.02 ± 7.95 ng/mL) was significantly higher than in the control group (P < 0.001) (6.46 ± 2.08) (Figure 1). The median serum Nampt protein level was 14.74 ng/mL (range 3.44-50.15). The below median and above median levels were respectively found in 66 (50.4%) and 65 (49.6%) patients.

Of 131 BC patients genotyped for rs61330082, 39 were CC homozygous, 60 CT heterozygous, and 32 TT homozygous. All observed genotype frequencies were in agreement with the Hardy-Weinberg equilibrium expectations. One-way ANOVA analysis revealed no significant differences in serum Nampt level between the three genotypes (Figure 2).

**Relationship between serum Nampt protein level and clinical pathological features of patients with BC**

No significant correlation in BC patients was observed between serum Nampt protein level and clinical pathological features, including age, sex, smoking status, tumor grade, invasiveness, metastasis, and recurrence (Table 2).

**Prognostic value of serum Nampt level**

Cox multivariable regression analysis showed that serum Nampt level was an independent prognostic marker of
non-muscle-invasive BC, with higher level (>14.74 ng/mL) indicating shorter recurrence-free survival rate (hazard ratio = 2.85, 95% confidence interval = 1.01-8.06, \( P = 0.048 \)) (Table 3). However, there was no significant association of serum Nampt level with RFS or OS in total BC patients and muscle-invasive BC patients (Figure 3).

### Table 2. The relationship between serum nicotinamide phosphoribosyltransferase (Nampt) and clinical pathological features of patients with bladder cancer

| Pathological features       | Serum Nampt N (%) | Odds ratio (95% confidence interval) | \( P \) (\( \chi^2 \) test) |
|----------------------------|-------------------|--------------------------------------|-----------------------------|
|                            | \(<14.74\) ng/mL  | \(>14.74\) ng/mL                     |                              |
| Age ≤64                    | 57 (43.5)         | 24                                   | 1 (referent)                |
| Sex ≥64                    | 74 (56.5)         | 42                                   | 0.554 (0.276-1.114)         | 0.096 |
| Smoking No                 | 54 (41.2)         | 27                                   | 1 (referent)                |
| Smoking index ≤400         | 36 (27.5)         | 19                                   | 0.895 (0.385-2.081)         | 0.796 |
| Smoking index >400         | 41 (31.3)         | 20                                   | 1.050 (0.466-2.365)         | 0.906 |
| Grade Low                  | 60 (45.8)         | 28                                   | 1 (referent)                |
| High                       | 71 (54.2)         | 38                                   | 0.760 (0.382-1.513)         | 0.434 |
| Invasiveness Non-muscle-invasive | 59 (45.0)   | 29                                   | 0.094 (0.549-2.177)         | 0.799 |
| Relapse No                 | 90 (68.7)         | 48                                   | 1 (referent)                |
| Yes                        | 41 (31.3)         | 18                                   | 1.460 (0.695-3.070)         | 0.317 |
| Metastases No              | 111 (84.7)        | 55                                   | 1 (referent)                |
| Yes                        | 20 (15.3)         | 11                                   | 0.804 (0.309-2.091)         | 0.654 |

### Table 3. Association between nicotinamide phosphoribosyltransferase (Nampt) level and patient’s survival

| Characteristics             | Multivariate survival analysis | Univariate survival analysis |
|-----------------------------|--------------------------------|------------------------------|
|                            | Recurrence-free survival*     | Overall survival*            | Recurrence-free survival    | Overall survival    |
|                             | Hazard ratio 95% confidence interval | P | Hazard ratio 95% confidence interval | P | Hazard ratio 95% confidence interval | P |
| Total ≤14.74 ng/mL          | 66 1 1                          | 1 1                           | 1 1                         |
| >14.74 ng/mL                | 65 1.19 0.64-2.23 0.583         | 0.94 0.37-2.39 0.888          | 1.21 0.65-2.25 0.551        | 0.79 0.31-2.01 0.624 |
| Muscle-invasive ≤14.74 ng/mL | 37 1 1                          | 1 1                           | 1 1                         |
| >14.74 ng/mL                | 35 0.93 0.36-2.44 0.887         | 0.60 0.19-1.86 0.374          | 0.86 0.33-2.23 0.752        | 0.62 0.20-1.91 0.405 |
| Non-muscle-invasive ≤14.74 ng/mL | 29 1 1                          | 1 1                           | 1 1                         |
| >14.74 ng/mL                | 30 2.85 1.01-8.06 0.048         | 3.02 0.39-23.37 0.291         | 2.02 0.85-4.79 0.110        | 1.46 0.24-8.73 0.679 |

*Adjusted for age, sex, smoking status, tumor stage, and tumor grade.
†Significant results are marked in bold.
DISCUSSION

Our study showed that serum Nampt level may serve as a biomarker of BC and an independent prognostic marker of non-muscle-invasive BC, with higher serum Nampt level indicating shorter recurrence-free survival rate. The use of biomarkers can provide detailed insight into cancer progression and metastasis, leading to more accurate and patient-specific prognosis and surveillance, and it can improve patients’ quality of life by enabling the use of less-aggressive treatment options (18,19).

Human Nampt was originally characterized as a presumptive cytokine named pre-B-cell colony enhancing factor (PBEF) (20). Nampt was also claimed to function as an insulin-mimetic adipocytokine named visfatin (21). Nampt exists in 2 known forms, iNampt and eNampt. iNampt is involved in angiogenesis by activating the extracellular signal regulated kinase (ERK)1/2 pathway and inducing vascular endothelial growth factor and MMP2/9 production (22). Additionally, it induces the proliferation and capillary-like tube formation in human umbilical vein endothelial cells in a dose- and time-dependent manner (23). These findings suggest that iNampt might have pro-angiogenic activity and support the growth of some types of tumors. Additionally, a chemical screen performed to identify compounds that might affect mechanisms of cellular growth, survival, or death has yielded a potent small molecule inhibitor termed FK-866 (24). eNampt acts as a cytokine, independent of its enzymatic activity, and plays a major role in the regulation of immune responses (16).

Nampt is expressed throughout the body and secreted mainly by adipocytes and macrophages (25). Its activity has been shown to enhance cellular proliferation (26) and to tip the balance toward cell survival following a genotoxic insult (27). Also, Nampt plays a central role in controlling the circadian clock machinery by dictating the periodical oscillations of some of its key transcription factors (28). At the immune level, it has been shown to promote myeloid (29) and lymphoid (30) differentiation and to increase specific cytokine production (31). The complex regulatory network should in principle disqualify Nampt as an inhibitor termed FK-866 (24). eNampt acts as a cytokine, independent of its enzymatic activity, and plays a major role in the regulation of immune responses (16).

Nampt is expressed throughout the body and secreted mainly by adipocytes and macrophages (25). Its activity has been shown to enhance cellular proliferation (26) and to tip the balance toward cell survival following a genotoxic insult (27). Also, Nampt plays a central role in controlling the circadian clock machinery by dictating the periodical oscillations of some of its key transcription factors (28). At the immune level, it has been shown to promote myeloid (29) and lymphoid (30) differentiation and to increase specific cytokine production (31). The complex regulatory network should in principle disqualify Nampt as a potential target for pharmacological intervention. Indeed, reduced NAD+ levels should affect the activity of several sirtuin members, causing multiple, and possibly unrelated, biological effects in vivo (32).

Other studies found that serum Nampt protein level was associated with tumor progression in patients with gastric cancer (33) and colorectal cancer (11). Nampt expression together with p53 expression was associated with shorter survival of glioblastoma patients (34). Nampt overexpression was also found to predict poor response to doxorubicin-based chemotherapy in breast cancer treatment (35). Our study contributed to this body of evidence by showing that serum Nampt level may be an independent prognostic marker of non-muscle-invasive BC, with higher serum Nampt level indicating shorter recurrence-free survival rate.

Our previous study showed that rs61330082 in NAMPT promoter region may predict BC risk and prognosis (17). However, in this study there was no significant difference between the three genotypes in serum Nampt level, which implies that rs61330082 may not affect the bladder cancer risk and prognosis via influencing the serum Nampt level.

In conclusion, our study presents a novel finding that serum Nampt level may serve as biomarker of BC and an independent prognostic marker of non-muscle-invasive BC. Nampt may be therefore a promising target for BC treatment, but its exact function in BC remains to be evaluated.

Funding This work was supported by the National Natural Science Foundation of China (No. 81172440, No. 81172494, No. 81202023 and No. 81272821); the Applied Basic Research Programs of Science and Technology Commission of Foshan Province (No. 2012520008); and Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT0935).

Ethical approval received from the ethics committee of the West China Hospital of Sichuan University.

Declaration of authorship KZ, BZ, and LZ contributed to research design; PZ, ZZ, and PC performed the sample collection; YP and YS performed the experiment; KZ and BZ performed data analysis; KZ wrote the manuscript; and LZ revised the manuscript.

Competing interests All authors have completed the Unified Competing Interest form at www.cmj.org/coa_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work.

Reference

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289-93. Medline:19219610 doi:10.1007/s00345-009-0383-3
2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315-30. Medline:14750899 doi:10.1007/BF03262330
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300. Medline:20610543 doi:10.3322/caac.20073
4. Cancer incidence in five continents. Volume IX. IARC Sci Publ.
Soloway MS, Sofer M, Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573-83. Medline:11912367 doi:10.1016/S0022-5347(05)6157-9

Saad A, Hanbury DC, McNicholas TA, Boustedt GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int. 2002;89:369-73. Medline:11872026 doi:10.1046/j.1464-4096.2001.01699.x

Sylvester RJ, van der Ma, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-70. Medline:12394686 doi:10.1016/S0022-5347(05)64273-5

Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279:50754-63. Medline:15381699 doi:10.1074/jbc.M408388200

Hutton SE, Moerkert PT, Brandwijk RJ, van der Ma, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964-70. Medline:12394686 doi:10.1016/S0022-5347(05)64273-5

Van Beijnum Jr, Moerkert Pt, Gerbers aJ, de Bruine aP , arends JW, hoogenboom hr, et al. Target validation for genomics using hybridization. FeBS Lett. 1999;463:77-82. Medline:10601642 doi:10.1016/S0014-5793(99)01578-1

Feifer AH, Taylor JM, Tarin TV, Herr HW. Maximizing cure for muscle-invasive bladder cancer: integration of surgery and chemotherapy. Eur Urol. 2011;59:978-84. Medline:21257257 doi:10.1016/j.euro.2011.01.014

Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59:1009-18. Medline:21454009 doi:10.1016/j.euro.2011.03.023

Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431-7. Medline:8289818

Kim SR, Bae SK, Choi KS, Park SJ, Park SO, Lee JF, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357:150-6. Medline:17408594 doi:10.1016/j.bbrc.2007.03.105

Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356-65. Medline:18093986 doi:10.1093/cvr/cvm111

Hasmann M, Schmaina I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63:7436-42. Medline:14612543

Friebie D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63:7436-42. Medline:14612543

Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81:370-80. Medline:18952695 doi:10.1093/cvr/cvn288

Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, et al.
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell. 2007;130:1095-107. Medline:17889652 doi:10.1016/j.cell.2007.07.035

28 Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science. 2009;324:654-7. Medline:19286518 doi:10.1126/science.1170803

29 Skokowa J, Lan D, Thakur BK, Wang F, Gupta K, Cario G, et al. NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)–sirtuin-1-dependent pathway. Nat Med. 2009;15:151-8. Medline:19182797 doi:10.1038/nm.1913

30 Rongvaux A, Galli M, Denanglaire S, Van Gool F, Dreze PL, Szpirer C, et al. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol. 2008;181:4685-95. Medline:18802071 doi:10.4049/jimmunol.181.7.4685

31 Van Gool F, Galli M, Gueydan C, Kruys V, Prevot PP, Bedalov A, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat Med. 2009;15:206-10. Medline:19151729 doi:10.1038/nm.1906

32 Galli M, Van Gool F, Rongvaux A, Andris F, Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2010;70:8-11. Medline:20028851 doi:10.1158/0008-5472.CAN-09-2465

33 Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Kaitai H, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol. 2009;44:685-90. Medline:19430715 doi:10.1007/s00535-009-0063-5

34 Reddy PS, Umesh S, Thota B, Tandon A, Pandey P, Hegde AS, et al. PBEF1/NAMPTase/Visfatin: a potential malignant astrocytoma/glioblastoma serum marker with prognostic value. Cancer Biol Ther. 2008;7:663-8. Medline:18728403 doi:10.4161/cbt.7.5.5663

35 Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res. 2005;11:7434-43. Medline:16243817 doi:10.1158/1078-0432.CCR-04-0548